Correlation Between Transcode Therapeutics and Phio Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Transcode Therapeutics and Phio Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Transcode Therapeutics and Phio Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Transcode Therapeutics and Phio Pharmaceuticals Corp, you can compare the effects of market volatilities on Transcode Therapeutics and Phio Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Transcode Therapeutics with a short position of Phio Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Transcode Therapeutics and Phio Pharmaceuticals.

Diversification Opportunities for Transcode Therapeutics and Phio Pharmaceuticals

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Transcode and Phio is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Transcode Therapeutics and Phio Pharmaceuticals Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Phio Pharmaceuticals Corp and Transcode Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Transcode Therapeutics are associated (or correlated) with Phio Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Phio Pharmaceuticals Corp has no effect on the direction of Transcode Therapeutics i.e., Transcode Therapeutics and Phio Pharmaceuticals go up and down completely randomly.

Pair Corralation between Transcode Therapeutics and Phio Pharmaceuticals

Given the investment horizon of 90 days Transcode Therapeutics is expected to under-perform the Phio Pharmaceuticals. In addition to that, Transcode Therapeutics is 1.03 times more volatile than Phio Pharmaceuticals Corp. It trades about -0.31 of its total potential returns per unit of risk. Phio Pharmaceuticals Corp is currently generating about -0.13 per unit of volatility. If you would invest  313.00  in Phio Pharmaceuticals Corp on August 23, 2024 and sell it today you would lose (60.00) from holding Phio Pharmaceuticals Corp or give up 19.17% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Transcode Therapeutics  vs.  Phio Pharmaceuticals Corp

 Performance 
       Timeline  
Transcode Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Transcode Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Transcode Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Phio Pharmaceuticals Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Phio Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's forward indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Transcode Therapeutics and Phio Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Transcode Therapeutics and Phio Pharmaceuticals

The main advantage of trading using opposite Transcode Therapeutics and Phio Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Transcode Therapeutics position performs unexpectedly, Phio Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will offset losses from the drop in Phio Pharmaceuticals' long position.
The idea behind Transcode Therapeutics and Phio Pharmaceuticals Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data